Novel treatment of retina and nerve using laminin
AssigneesKyoto Prefectural Public University Corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.
InventorsNoriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
Life of this patent
Estimating the term…
Abstract
The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.
Claims20
A method for treating or preventing a disease, a disorder, or a condition of a retinal pigment epithelium of a subject, comprising administering an effective amount of at least one agent selected from the group consisting of laminins and fragments thereof to the subject, wherein the laminins comprise a γ1 chain.
(canceled)
A method for a disease, a disorder, or a condition of a nerve requiring cell transplantation in a subject, comprising administering at least one agent selected from the group consisting of laminin 511 and fragments thereof to the subject.
(canceled)
Dependencies are inferred from the claim text.